Bharat Biotech To Acquire GSK's Indian Rabies Vaccine Producing Arm
--Must See--

Bharat Biotech To Acquire GSK’s Indian Rabies Vaccine Producing Arm

February 15, 2019, announcement was made that Bharat Biotech is acquiring Chiron Behring Vaccines Pvt Ltd, located in Ankleshwar from GlaxoSmithKline (GSK). The valuation of the deal has not been disclosed yet. Via this move, scientist turned entrepreneur – Krishna Ella, Bharat Biotech’s co-founder harbors hopes of making a dent in international vaccine space and the Indian.

In the coming week, the deal is intended to be complete, Wherein Bharat Biotech will take over 100% equity stake in Chiron Behring Vaccines in an all-cash transaction, which in short will make Bharat have within its fold the largest capacity in the world to make rabies vaccine.

Highlighting the shortage of Rabies vaccine in India as well abroad, Ella stated that With this deal, our combined capacity will become 25 million doses. However, the country needs about 35 million doses, as nearly some 1.7 million dog bites incidents occur every year.

Krishna Ella said Bharat Biotech is working towards expanding its portfolio and in another few years, they hope to get a portfolio much wider than other leading MNCs in the space. He also added that the company currently has 16 vaccines and in a span of three to

four years they plan to have a portfolio of about 22 vaccines. Significant among them now is the WHO pre-qualified vaccines Bipolio, Rotavac and Typbar TVC to combat polio, rotavirus & typhoid infections.

40-60 percent of Chiron’s output will be shifted by Bharat Biotech to the domestic market. Only 50 percent of rabies vaccine requirement is being met in India till now.